Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 19;14:2861. doi: 10.1038/s41467-023-38581-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — a Kaplan-Meier overall survival plot comparing gastric cancer patients with high ADAR1 and high SCD1 proteomic expression versus low ADAR1 and low SCD1 proteomic expression. All gastric cancer patients were treated with a combination of 5FU and platinum-based chemotherapy in an adjuvant clinical setting. b Expression level of ADAR1 and SCD1 and its correlation with percent tumor remaining. All gastric cancer patients were treated with a combination of 5FU and platinum-based chemotherapy in a neoadjuvant clinical setting. c Pearson correlation analysis of ADAR1 mRNA expression with SCD1 editing in TCGA-STAD. d ADAR1 mRNA expression in responder versus non-responder to chemotherapy treatment in TCGA-STAD. e ADAR1 mRNA/SCD1 editing signature in responder versus non-responder to chemotherapy in TCGA-STAD. f Kaplan-Meier overall survival plot comparing patients with ADAR1 mRNA/SCD1 editing signature >0 with ADAR1 mRNA/SCD1 editing signature <0. For panels (d-f), only GC patients of intestinal subtype treated with 5FU or platinum-based chemotherapy were considered. Significance were calculated by (a, f) log-rank test; (b, d, e) unpaired two-tailed student t-test; (c) two-tailed Pearson correlation analysis. All data was presented as mean ± standard deviation. Source data are provided as a Source Data file.